Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
INTERVENTIONAL
Inicio: 1 de abr de 2013
ID: NCT01949129
Activo, no recluta
ClinicalTrials.gov
A Real World Evidence Prospective Cohort Study in the Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective
OBSERVATIONAL
Inicio: 8 de mar de 2019
ID: NCT03935763
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Double Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Oxaliplatin and Fluoropyrimidine Containing Regimen
INTERVENTIONAL
Inicio: 1 de mar de 2007
ID: NCT00454116
Terminado
Fase 2
ClinicalTrials.gov
Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)
INTERVENTIONAL
Inicio: 1 de nov de 2011
ID: NCT01512199
Retirado
Fase 2
ClinicalTrials.gov
A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L)1 Immunotherapy
INTERVENTIONAL
Inicio: 15 de abr de 2021
ID: NCT04151563
Completado
ClinicalTrials.gov
Prevalence of the Mutational Status of KRAS in mCRC in Argentine Patients
OBSERVATIONAL
Inicio: 1 de jun de 2009
ID: NCT01082757
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
INTERVENTIONAL
Inicio: 27 de feb de 2025
ID: NCT06731478
Activo, no recluta
Fase 3
ClinicalTrials.gov
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
INTERVENTIONAL
Inicio: 19 de nov de 2015
ID: NCT02531516
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)
INTERVENTIONAL
Inicio: 26 de jun de 2019
ID: NCT03976375
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
INTERVENTIONAL
Inicio: 7 de dic de 2018
ID: NCT03701334
Terminado
ClinicalTrials.gov
A NIS of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer in Argentina and Brazil -LATAM AVENUE
OBSERVATIONAL
Inicio: 18 de ene de 2023
ID: NCT05568407
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 14 de sept de 2016
ID: NCT02747004
Completado
Fase 2
ClinicalTrials.gov
A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)
INTERVENTIONAL
Inicio: 1 de jul de 2011
ID: NCT01367665
Terminado
Fase 3
ClinicalTrials.gov
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
INTERVENTIONAL
Inicio: 10 de may de 2021
ID: NCT04752332
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
INTERVENTIONAL
Inicio: 2 de oct de 2020
ID: NCT04590963
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
INTERVENTIONAL
Inicio: 18 de ago de 2025
ID: NCT07005128
Completado
Fase 3
ClinicalTrials.gov
An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.
INTERVENTIONAL
Inicio: 1 de jun de 2009
ID: NCT00760877
Completado
Fase 3
ClinicalTrials.gov
An Open-Label Randomized International Multi-Center Phase III Study of Capecitabine (Xeloda) in Combination With Cisplatin Versus FU/Cisplatin in Patients With Advanced and/or Metastatic Gastric Cancer
INTERVENTIONAL
Inicio: 1 de abr de 2003
ID: NCT02563054
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
INTERVENTIONAL
Inicio: 11 de jun de 2024
ID: NCT06305754
Completado
ClinicalTrials.gov
ARI103094-Follow-Up Study for REDUCE Study Subjects
OBSERVATIONAL
Inicio: 9 de abr de 2009
ID: NCT00883909
Anterior
1
...
17
18
19
...
434
Siguiente
Filtros